Nasdaq
$590.00▲ 0.46%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $25.04BShares out 42.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
103- 1d agoAfter-hours26.10.24 05:354Ownership#●●●
UNITED THERAPEUTICS Corp
United Therapeutics Corp executive Martine A. Rothblatt filed a Form 4 on October 23, 2026, reporting changes in beneficial ownership of securities as of October 22, 2026. This filing serves as a standard disclosure regarding insider stock holdings.…more
$590.00+0.46%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 2d agoAfter-hours26.10.23 05:364Ownership
UNITED THERAPEUTICS Corp
Martine A. Rothblatt, CEO of United Therapeutics Corp, filed a Form 4 statement regarding changes in beneficial ownership of company securities on October 21, 2026. This filing serves as a standard disclosure of changes in executive stock holdings.…more
$590.00+0.46%vs prev closeView filingShare - 2d agoPre-market26.10.22 20:008-KKey event
UNITED THERAPEUTICS Corp
United Therapeutics Corporation (UTHR) announced that its Board of Directors has authorized a new share repurchase program of up to $2 billion. This authorization is effective for one year, ending on October 21, 2027, and the company may execute repurchases through open market transactions, private negotiations, or other methods depending on market conditions.…more
$590.00+0.46%vs prev closeView filingShare
102 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.22 20:11Bullish#●●●#●●●
United Therapeutics Authorizes New $2B Share Repurchase Program
United Therapeutics has approved a new $2 billion share repurchase program effective through October 2027. This move reflects the company's commitment to returning capital to shareholders and supporting its stock value.…more
$590.00+0.46%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 4d agoPre-market26.10.20 20:07
●●●●●●●● ●●●●● ●●●●●●
United Therapeutics has opened its third designated pathogen-free facility in Houston to scale the production of xenokidneys and xenohearts. This facility is essential for advancing the company's organ manufacturing program and preparing for future commercial production.…more
$590.00+0.46%vs prev closeShareBenzinga - 5d agoPre-market26.10.19 20:09
●●●●●●●● ●●●●● ●●●●●●
United Therapeutics has received FDA clearance to proceed with a phase 2 clinical trial for its treprostinil SMI inhaler in patients with PH-COPD. While the company anticipates significant market growth if the trial succeeds, the product remains in the investigational stage.…more
$590.00+0.46%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report